Abstract
While the debate remains largely open concerning the importance of purging in malignant hemopathies, we are currently witness to the extraordinary development of complex and expensive technologies associating several methods (immunochemoseparation procedure, drug cocktails …). Such techniques may be justified for acute leukemias at high risk of relapse when the residual disease is almost perceptible. Current objectives are oriented in several directions: development of techniques for detecting residual disease, development of immunophysical procedure (magnetic and floating immunobeads) and long-term human marrow cultures for selection of normal hematopoietic stem cells. Future progress in ABMT depends not only on the effective ex-vivo purging of marrow but also on development of more effective conditioning regimens ( in vivo purging).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.